NY-DILIGENT/INSIGHTIA
11.1.2022 14:02:12 CET | Business Wire | Press release
Diligent , the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced that it has acquired Insightia, a leading SaaS provider of expert insights and intelligent analytics for listed companies, with a focus on shareholder activism, proxy voting and corporate governance. Financial terms of the transaction were not disclosed.
Formed from the 2020 merger of Activist Insight and Proxy Insight, Insightia offers a single source of global public company information to a range of global investment banks, law firms, proxy solicitors, and other corporate advisors. Representative clients include PJT CamberView, Glass Lewis, Morrow Sodali, FTI Consulting, and Georgeson.
Bringing together Diligent’s leading governance, analytics and ESG solutions with Insightia’s vital intelligence across a variety of public company data will provide clients with even more meaningful insights to power their board and organizations’ governance practices. Clients will have access to a rich ecosystem of organizational risk assessments and data tools in areas spanning board composition, executive compensation, supply chain due diligence, and ESG standards and frameworks. Diligent will also pursue a range of potential solution integrations with Insightia, including adding activist investor alerts within its Boards application, enabling clients to better monitor susceptibility to activism.
Brian Stafford, CEO of Diligent, said: “From our regular interactions with board members, business leaders and investors, we understand that having access to the most comprehensive and relevant data facilitates better guidance and confident decision-making. That is why we are so pleased to bring onboard Insightia’s deep experience and market-leading intelligent analytics, particularly against the backdrop of a marketplace where shareholder engagement is rapidly evolving. Current and future clients can look forward to even more insights on the issues that matter most so that they can continue to build successful, equitable and sustainable organizations.”
Kerry Pogue, Co-Founder and CEO of Insightia, said: “We are excited to benefit from Diligent’s expertise and resources as a leading SaaS organization in this next phase of Insightia’s growth journey. Combining our capabilities with Diligent’s governance, analytics and ESG solutions is a compelling next step as we look to scale our offerings globally for the benefit of our clients. Both companies are incredibly complementary in terms of their strategy and culture, and our team looks forward to being part of Diligent and accelerating the reach of our mission.”
District Capital Partners served as the exclusive financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. Taylor Wessing served as the legal advisor to Insightia.
About Diligent Corporation
Diligent is the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG to over 1 million users from over 25,000 customers around the world. Our innovative technology gives leaders a connected view of governance, risk, compliance and ESG across their organizations, sparking the insights they need to make better decisions and lead with purpose. Learn more at diligent.com .
About Insightia
Headquartered in London, Insightia was formed in 2020 through the merger of Activist Insight and Proxy Insight, who together have provided a variety of shareholder activism, shareholder voting, and corporate governance data to a global client base for the past decade. Insightia’s mission is to improve engagement, stewardship and corporate governance through the delivery of timely intelligence to key stakeholders and their advisors. Learn more at insightia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005384/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom